Thomas J Raub

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint P-glycoprotein recognition of substrates and circumvention through rational drug design
    Thomas J Raub
    Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Mol Pharm 3:3-25. 2006
  2. doi request reprint Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft
    Thomas J Raub
    Drug Disposition, Lilly Research Laboratories T J R, G N W, P K, B A S, R T A, G A S, Division of Cancer Research L M G, H E S, and Discovery Chemistry Research and Technologies A D D, Eli Lilly and Company, Indianapolis, Indiana Discovery Chemistry Research and Technologies, Eli Lilly and Company, Alcobendas, Madrid, Spain C S M and Covance Laboratories, Greenfield, Indiana H E S
    Drug Metab Dispos 43:1360-71. 2015
  3. doi request reprint Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux
    Prashant V Desai
    Computational ADME, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Mol Pharm 10:1249-61. 2013
  4. ncbi request reprint QSAR Model of Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain: Incorporating P-glycoprotein Efflux as a Variable
    Elena Dolgikh
    Global Scientific Informatics, Advanced Analytics, Computational ADME, IT Informatics and Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
    J Chem Inf Model 56:2225-2233. 2016
  5. doi request reprint How hydrogen bonds impact P-glycoprotein transport and permeability
    Prashant V Desai
    Computational ADME, Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Bioorg Med Chem Lett 22:6540-8. 2012
  6. doi request reprint Chalcogenopyrylium dyes as inhibitors/modulators of P-glycoprotein in multidrug-resistant cells
    Geri A Sawada
    Drug Disposition, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Bioorg Med Chem 16:9745-56. 2008
  7. ncbi request reprint Automated analysis of polyethylene glycol-induced inhibition of P-glycoprotein activity in vitro
    Erin D Hugger
    Pharmaceutical Chemistry Department, The University of Kansas, Lawrence, Kansas 66047, USA
    J Pharm Sci 92:21-6. 2003
  8. ncbi request reprint Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonists
    Daniel P Walker
    Neuroscience Research, Pfizer Global Research and Development, Eastern Point Rd, Groton, CT 06340, USA
    Bioorg Med Chem 14:8219-48. 2006
  9. doi request reprint ATP occlusion by P-glycoprotein as a surrogate measure for drug coupling
    Gregory Tombline
    Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, New York 14260 3000, USA
    Biochemistry 47:3294-307. 2008

Collaborators

  • Prashant V Desai
  • Palaniappan Kulanthaivel
  • Gregory Tombline
  • MICHAEL DETTY
  • Erin D Hugger
  • Geri A Sawada
  • Elena Dolgikh
  • Daniel P Walker
  • Timothy M Jones
  • Ian A Watson
  • Stuart Morton
  • Teiah M Moore
  • J William Higgins
  • Nancy K Brennan
  • Luz A Cortes-Burgos
  • Eric P Seest
  • Barbara A Olson
  • Mihaly Hajos
  • Karen M Yates
  • Bruce A Thornburgh
  • Donn G Wishka
  • Vincent E Groppi
  • Bruce N Rogers
  • William E Hoffmann
  • Matthew R Hester
  • Kai S Li
  • Brad A Acker
  • E Jon Jacobsen
  • Erik H F Wong
  • Shaojuan Jia
  • Theron M Wall
  • Laura Fitzgerald
  • Brandon J Margolis
  • Jason K Myers
  • Raymond S Hurst
  • Nicole R Higdon
  • Mark L Wolfe
  • Steven C Reitz
  • Brian A Staton
  • Tatiana N Vetman
  • Lester A Dolak
  • Fusen Han
  • David W Piotrowski
  • Paula M Tinholt
  • Rodney R Walters

Detail Information

Publications9

  1. ncbi request reprint P-glycoprotein recognition of substrates and circumvention through rational drug design
    Thomas J Raub
    Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Mol Pharm 3:3-25. 2006
    ..This review discusses our understanding of how P-gp recognizes and pumps compounds as substrates and describes cases where structural changes were made in a chemical scaffold to circumvent the effects of P-gp interactions...
  2. doi request reprint Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft
    Thomas J Raub
    Drug Disposition, Lilly Research Laboratories T J R, G N W, P K, B A S, R T A, G A S, Division of Cancer Research L M G, H E S, and Discovery Chemistry Research and Technologies A D D, Eli Lilly and Company, Indianapolis, Indiana Discovery Chemistry Research and Technologies, Eli Lilly and Company, Alcobendas, Madrid, Spain C S M and Covance Laboratories, Greenfield, Indiana H E S
    Drug Metab Dispos 43:1360-71. 2015
    ....
  3. doi request reprint Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux
    Prashant V Desai
    Computational ADME, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Mol Pharm 10:1249-61. 2013
    ..Key learning based on our experience with P-gp can be widely applicable across other DMPK-related challenges...
  4. ncbi request reprint QSAR Model of Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain: Incorporating P-glycoprotein Efflux as a Variable
    Elena Dolgikh
    Global Scientific Informatics, Advanced Analytics, Computational ADME, IT Informatics and Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
    J Chem Inf Model 56:2225-2233. 2016
    ....
  5. doi request reprint How hydrogen bonds impact P-glycoprotein transport and permeability
    Prashant V Desai
    Computational ADME, Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Bioorg Med Chem Lett 22:6540-8. 2012
    ..Using various examples from literature, we illustrate the benefits of considering the relative strengths of individual H-bonds and introducing intramolecular H-bonds to increase membrane permeability and/or decrease P-gp efflux...
  6. doi request reprint Chalcogenopyrylium dyes as inhibitors/modulators of P-glycoprotein in multidrug-resistant cells
    Geri A Sawada
    Drug Disposition, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Bioorg Med Chem 16:9745-56. 2008
    ..3 x 10(-6)M) and within inside-out membrane vesicles (IC(50) of 9.6 x 10(-6)M). Yet, Pgp did not influence the distribution of 8-Te in MDCKII-MDR1 monolayers suggesting that 8-Te may bind to an allosteric site...
  7. ncbi request reprint Automated analysis of polyethylene glycol-induced inhibition of P-glycoprotein activity in vitro
    Erin D Hugger
    Pharmaceutical Chemistry Department, The University of Kansas, Lawrence, Kansas 66047, USA
    J Pharm Sci 92:21-6. 2003
    ....
  8. ncbi request reprint Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonists
    Daniel P Walker
    Neuroscience Research, Pfizer Global Research and Development, Eastern Point Rd, Groton, CT 06340, USA
    Bioorg Med Chem 14:8219-48. 2006
    ..At least one analog from each series (1h, 1o, 2a, 9a, and 18a) shows an improved hERG safety profile over PNU-282,987...
  9. doi request reprint ATP occlusion by P-glycoprotein as a surrogate measure for drug coupling
    Gregory Tombline
    Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, New York 14260 3000, USA
    Biochemistry 47:3294-307. 2008
    ..It is noteworthy that when compared to previously reported TMR analogues, subtle modification of the TMR scaffold can confer large differences in ATP turnover...